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Abstract: Intrinsically disordered proteins (IDPs) are proteins that usually do not adopt 
well-defined native structures when isolated in solution under physiological conditions. 
Numerous IDPs have close relationships with human diseases such as tumor, Parkinson 
disease, Alzheimer disease, diabetes, and so on. These disease-associated IDPs commonly 
play principal roles in the disease-associated protein-protein interaction networks. Most of 
them  in  the  disease  datasets  have  more  interactants  and  hence  the  size  of  the 
disease-associated IDPs interaction network is simultaneously increased. For example, the 
tumor suppressor protein p53 is an intrinsically disordered protein and also a hub protein in 
the p53 interaction network; α-synuclein, an intrinsically disordered protein involved in 
Parkinson diseases, is also a hub of the protein network. The disease-associated IDPs may 
provide  potential  targets  for  drugs  modulating  protein-protein  interaction  networks. 
Therefore, novel strategies for drug discovery based on IDPs are in the ascendant. It is 
dependent on the features of IDPs to develop the novel strategies. It is found out that IDPs 
have unique structural features such as high flexibility and random coil-like conformations 
which enable them to participate in both the ―one to many‖ and ―many to one‖ interaction. 
Accordingly, in order to promote novel strategies for drug discovery, it is essential that 
more and more features of IDPs are revealed by experimental and computing methods. 
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1. Introduction   
According  to  the  traditional  sequence-to-structure-to-function  paradigm,  active  proteins  have 
well-defined three-dimensional structures under physiological conditions. However, as early as in the 
1990s, it was reported that there is another class of proteins, which have no well-defined structures 
under  physiological  conditions,  but  still  have  biological  functions  [1,2].  These  proteins  with 
intrinsically disordered regions (IDRs) are called intrinsically disordered proteins (IDPs). IDRs are 
defined  as  the  regions  that  do  not  adopt  any  well-defined  three-dimension  structures  under 
physiological  conditions.  IDPs  are  also  called  natively  unfolded  [2],  natively  denatured  [3],  and 
intrinsically  unstructured  proteins  [4].  It  has  been  established  that  IDPs  lack  stable  tertiary  or 
secondary structures under physiological conditions in vitro, they have high flexibility and random 
coil-like conformation, and they are highly abundant in nature [3]. In fact, it has been predicted that 
more than 30% of all eukaryotic proteins belong to this type [3]. The sequences of IDPs have low 
hydrophobicity, and they are substantially enriched in polar (such as R, G, Q, S, P, E, and K) and 
structure-breaking (such as G and P), disorder-promoting amino acid residues [3]. IDPs have unique 
structural features that enable them to participate in both one to many and many to one signaling, and 
they also have unique biophysical advantages, such as accessibility and space efficiency. IDPs are 
usually hub proteins in protein and other molecules interaction networks [5]. Recently, Uversky [6] 
concluded that the conformational behavior of IDPs is low cooperative. 
IDPs  play  crucial  roles  in  regulation,  recognition,  signaling,  and  control  of  protein-protein 
interaction networks. The importance of IDPs in biological functions is now being recognized. Some 
important endocytic proteins lack a tertiary structure and they play an important role in the field of 
endocytosis [7]. The functional repertoire of IDPs complements the functions of ordered proteins. 
They have close relationships with human diseases, such as tumor, amyloidoses, neurodegenerative 
diseases, cardiovascular disease and diabetes [5]. 
IDPs have brought great challenges to the classical structural and functional relationship of proteins, 
which  is  also  a  new  opportunity  to  reveal  the  essential  relationship  especially  for  these  types  of 
disordered proteins. At the same time, intrinsic disorder is very common in disease-associated proteins. 
Drug-discovery has been linked with functions of IDRs, and new drug discovery strategies are aimed 
at a wide variety of signaling and regulatory functions. Therefore, the IDPs could serve as potential 
targets for structure-based drug design based on their prime features. Furthermore, IDPs are usually 
hub  proteins  in  protein-protein  interaction  networks,  and  protein-protein  interaction  is  a  potential 
source for drug targets. In order to make full use of IDPs for drug discovery, it is important to study the 
characters  of  sequence,  structure,  dynamics,  biophysics  and  protein-protein  interaction  network  of 
these proteins. In this paper, we review characteristics of IDPs and highlight the novel strategies for 
drug discovery based on the updated research of IDPs.   Int. J. Mol. Sci. 2011, 12                         
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2. Sequence Characterizations of IDPs   
The  biologically  active  conformation  and  three-dimensional  structures  of  ordered  proteins  are 
determined by the amino acid sequences [8]. It could be deduced that the amino acid sequence also 
predominates  the  absence  of  ordered  structures.  IDPs  have  no  well-defined  structures  under 
physiological conditions, which may come from its sequence characters. Thus more and more studies 
are  focused  on  the  sequence  characters  of  IDPs  to  find  the  common  features  that  encode  the 
intrinsically disordered structures. 
By  analysis of amino acid  composition  of ordered  and disordered segments,  Dunker  et  al.  [9] 
divided the 20 amino acids into three groups. The first group is called order-promoting amino acid 
(namely C, W, Y, I, F, V and L) which is depleted in disordered segments. The second group is called 
disorder-promoting amino acid (namely M, K, R, S, Q, P and E) which is enriched in disordered 
segments, and the third group includes A, G, H, T, N and D, which have no obvious differences 
between ordered and disordered segments and are thus called neutral residues. As some proteins with 
similar  well-defined  ordered  structures  have  no  obvious  sequence  comparability,  there  are  also 
exceptions in the aforementioned class. The N-terminal (1~39) of p53 (p531–39) has been proved to be 
intrinsically disordered [10], but the content of leucine is up to 15.4% [11], which is thought to be an 
order-promoting amino acid and the statistical frequency value in disordered proteins is 5.44% [12], 
Leucine  plays  an  essential  role  in  the  formation  of  hydrophobic  cluster  and  the  leucine-rich 
hydrophobic cluster promotes the formation of a collapsed structure of p531–39 [11].   
Compared with ordered proteins, IDPs have a lower sequence complexity [13], a larger net charge 
and a lower content of hydrophobic amino acid residues [14]. Lower mean hydrophobicity can restrain 
the formation of hydrophobic cluster and higher net charge can help to form an extended conformation 
by electrostatic repulsion. Uversky et al. [15] estimated the boundary between ordered and intrinsically 
disordered  protein  segments  with  mean  net  charge  and  mean  hydrophobicity  value  as  reaction 
coordinates. However, protein Rv3221c is special, it is proved to be intrinsically disordered, but its 
amino acid composition reveals that it has 24% charged and 54.9% hydrophobic amino acid residues 
and it adopts structured conformation at high temperatures [16]. 
Another issue of great interest to researchers is the prediction of IDPs. With some common features 
of amino acids, it is easy to predetermine whether proteins with certain amino acid compositions are 
IDPs.  Disordered  protein  prediction  has  been  one  part  of  the  Critical  Assessment  of  Structure 
Prediction (CASP) from the 5th term [17], which is useful for inspiring rapid development. More than 
twenty  predictors  have  been  discussed  based  on  the  amino  acid  composition  of  the  protein 
sequence [18]  and  physicochemical  property  of  amino  acids  including  aromaticity,  net  charge, 
flexibility, and hydropathy [13]. DISOPRED [19] chooses 21 parameters per residue as input and 
metaPrDOS [20] takes meta approach integrating the results of seven different prediction methods to 
predicate disordered regions. Using Bayesian multinomial classifier, the predictive accuracy of 89.2% 
could be achieved for intrinsically disordered regions [21]. Although the current predictors have higher 
predictive accuracy [22], it is notable that there is a deficiency for the predictors on intrinsic disordered 
region. For example, the residues 1–172 region of SKIP was demonstrated to be an intrinsic disordered 
region (SKIP172) [23], but was not predicted by neural network method [24]. In order to improve the 
accuracy,  it  is  necessary  for  us  to  further  study  the  characters  of  IDPs  sequence  and  others. Int. J. Mol. Sci. 2011, 12                         
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Furthermore, the prediction of protein binding regions in IDPs is very important, ANCHOR [25,26] is 
an original method for the prediction of disordered binding regions that are disordered in isolation but 
can undergo disorder-to-order transition upon binding. 
3. Structural Characterizations of IDPs 
Investigations  of  the  structural  characteristics  of  IDPs  are  the  basis  to  reveal  the  molecular 
mechanism of their biological functions. Compared with structured proteins, IDPs are enriched in M, 
K, R, S, Q, P, E residues and possess a highly flexible, malleable random coil-like structure. The 
increased level of these residues makes them fail to fold into a fixed three-dimensional structure under 
physiological
  conditions  [27].  Moreover,  IDPs  are  composed  of  an  ensemble  of  highly   
heterogeneous conformations. 
At the structural level, Dunker et al. [3] had an alternative proposal called ―The protein trinity‖, 
which  proposed that intrinsically  disordered
 regions may  exist in  molten globule-like and random
 
coil-like forms. Additionally, the pre-molten globule has been proposed as another form of disorder 
state by Uversky et al. with ―The protein quartet‖ model [2]. The research results show that some 
residual structures have been confirmed in IDPs and they exhibit a rich diversity of local and even 
long-range structural preferences [28] as either coil-like or premolten-globule-like proteins [2]. 
The disorder of IDPs is crucial to their functions. The functions are considered to arise from any 
one of the three states or from transitions
 between disordered and ordered conformations [29]. The 
conformational changes associated with functions may
 be originated from alterations in environmental 
or cellular
 conditions.   
DisProt [30] is a database which provides structural and functional information of IDPs. Our group 
has been trying to construct a second database of IDPs and IDRs in order to provide latest information 
on sequence, structural, biophysical and functional characterizations of IDPs and IDRs. 
Human α-synuclein is a 140 amino acid-protein and its normal function is to bind to the surface of 
synaptic vesicles [31,32]. The oligomers of this protein have been linked to Parkinson’s disease and 
Lewy bodies. Typical of such ailments is the presence of α-synuclein aggregates in a β-structure that 
can be soluble
 or insoluble [33]. α-Synuclein protein is highly disordered when isolated in solution. 
The  structure  (PDB  ID:  1xq8)  of  micelle-bound  human  α-synuclein  has  been  discussed  by   
Ulmer et al. [34] and shown as a partially helical structure. More detailed studies showed that this 
structure could take the form of curved α-helices with a break in the 38–44 regions on the micelle 
surface [34–36]. On the contrary, an uninterrupted helix has been proposed when α-synuclein is bound 
to lipid vesicles [37–40]. In addition, the protein can apparently interchange between the curved-helix 
and  extended-helix  conformations,  in  the  presence  of  small  spheroidal  detergent  micelles,  the 
extended-helix  conformation  can  convert  into  a  curved-helix.  Membrane-bound  conformations  of 
α-synuclein likely mediate the protein’s function and play a role in the aggregation and toxicity of the 
protein. Recently, Georgieva et al. [41] studied the influence of different environments on structural 
character of α-synuclein, which concluded that: when α-synuclein is free in solution or in the absence 
of  membrane  or  detergent,  the  conformation  fluctuates  between  compact  and  extended;  when 
α-synuclein is in the detergent, the conformation selected is dependent on the detergent concentration; 
the membrane  environment  exerted  an influence on the conformation of  α-synuclein  protein.  The 
ability of several polyphenols (exifone) to inhibit the assembly of α-synuclein was investigated by Int. J. Mol. Sci. 2011, 12                         
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many researchers. Yamaguchi et al. [42] studied the characterization of exifone treated α-synuclein 
monomer  and  dimmer,  their  results  showed  N-terminal  region  (1–60)  is  involved  in  the 
inhibitor-induced dimerization. De Genst et al. [43] studied the structure and properties of a complex 
of α-synuclein and an antibody NbSyn2, and they found that NbSyn2 binds specifically to monomeric 
α-synuclein and interacts with four C-terminal residues of α-synuclein. 
The absence of well-defined structure for IDPs under the physiological condition without partner 
makes it impossible to obtain a unique high-resolution structure. The structural studies on IDPs are to 
gain  some  characteristic  parameters  (customarily  experimental  data)  of  ensemble  states  that  are 
sampled by polypeptide.   
Many experimental techniques applied to ordered proteins could also be applied to IDPs. With x-ray 
crystallography method,  disorder  results  in  missing  electron  density  in  determined  structures.  The 
region  without  coordinates  of  residues  atoms  in  crystal  structure  is  determined  as  intrinsically 
disordered [3]. Nuclear magnetic resonance (NMR) spectroscopy is a powerful technique for protein 
structure  determination  and  dynamics  characterization  in  solution.  With  the 
15N–
1H  heteronuclear 
nuclear overhauser effect (NOE) measurement, ordered residues hold positive values and disordered 
residues hold negative values [44,45]. Based on the NOE data, a series of consecutive positive value 
means  ordered  region  and  a  series  of  consecutive  negative  value  means  disordered  region. 
Paramagnetic  relaxation  enhancement  (PRE)  has  perhaps  been  the  most  successful  at  detecting 
long-range contacts in disordered protein ensembles [46,47]. In recent years, several other techniques 
have been used to identify IDPs, such as: residual dipolar couplings (RDCs) steady-state fluorescence 
spectroscopy [48], circular dichroism (CD), differential scanning calorimetry (DSC), surface plasmon 
resonance (SPR), electrospray mass spectrometry [49], Fourier transform infrared (FTIR) [16], Raman 
spectroscopy  and  Raman  optical  activity  [50].  In  general,  more  than  one  method  are  used 
synchronously [23,51–54]. 
In  addition,  computational  methods  increasingly  play  important  roles  in  depicting  disordered 
protein  structures  and  dynamics  behaviors  [5].  It  can  generate  de  novo  prediction  [11]  and 
experimental-data-based prediction [54]. With experimental data as ensemble average, computational 
simulation could study conformational characters in detail [55]. With computation simulations, p531–39 
shows bimodal behavior [11] which suggests the coexistence of both ordered and disordered structure 
in  solution.  Bimodal  behavior  has  been  suggested  to  be  an  intrinsic  characterization  of  IDPs  in   
solution [56]. Studies on IDPs have indicated that polar IDPs prefer ensembles of collapsed structures 
in aqueous solutions [50,57], and p531–39 has been observed to collapse more quickly than others with 
an  average  collapsing  time  of  52ns  starting  from  extended  conformation  [11].  Cao  et  al.  [58,59] 
investigated the structural and thermodynamics characters of α-syn12 peptide (residues 1-12 of the 
human α-synuclein protein) in aqueous solution, and they showed that the isolated α-syn12 peptide in 
water adopted four different conformational states. 
Although IDPs are similar in many aspects to proteins that are unfolded due to denaturation, they 
have striking differences [60]. The former tend to cluster in the mainly disordered/irregular region of 
the  non-linear  mapping  (NLM)  plot  and  appear  to  contain  a  significant  amount  of  the  extended 
PPII-helical  conformation;  whereas  the  latter  appear  in  other  regions  and  can  contain  significant 
amount  of  β-structure  in  the  case  of  reduced  proteins  and  α-helix  in  the  case  of  acid  molten   
globules [61]. Proline, a disordered-promoting amino acid, is known to disfavor a rigid secondary Int. J. Mol. Sci. 2011, 12                         
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structure but has a strong preference for the left-handed polyproline II (PP II) helix [62] and is the 
poorest β-strand-forming residue [61]. 
4. IDPs Interaction Networks 
4.1. The Human Disease Network and Diseasome   
Recently, a revolutionary concept named ―the diseasome‖, defined as a combined set of all known 
disorder/disease gene associations, offers a platform to explore, in a single graph-theoretic framework, 
all known phenotype and disease gene associations, thus indicating the common genetic origin of 
many diseases [63]. The human disease network is a set of all known human genetic diseases. In the 
human disease network (HDN) nodes represent disorders, and two disorders are connected to each 
other  if  they  share  at  least  one  gene  in  which  mutations  are  associated  with  both  disorders.  The 
diseasome is constructed based on the relationship between the human disease network and the disease 
gene  network  [63].  The  diseasome  provides  rapid  visual  references  of  the  genetic  links  between 
disorders and disease genes, indicating the possibility of discerning general patterns and principles of 
human  diseases  not  readily  apparent  from  the  study  of  individual  disorders.  HDN  reflects  the 
underlying cellular network-based relationship between genes and functional models.   
4.2. Unfoldome of Human Genetic Diseases 
The human-genetic-diseases-associated unfoldome, which is defined as the IDP-containing subset 
of a given genome, is associated with human genetic diseases [63–65]. It is reported that intrinsic 
disorder is  common in diseasome, and proteins  from  different  diseases possess different  levels  of 
intrinsic disorder. Many disordered regions are subjected to alternative splicing and contain specific 
molecular recognition features responsible for the protein-protein interactions. Many hub proteins are 
generally more disordered than non-hub proteins.   
4.3. IDPs in Human Protein-Protein Interactions 
IDPs are considered to play an important biological role in protein-protein interactions and have 
shown to participate in both one-to-many and many-to-one signaling. In order to understand the role of 
a protein in any cellular mechanism, it is critical to identify its gene networks. For example, there are 
147, 65 and 140 proteins involved in Huntington disease, Parkinson’s disease and Alzheimer’s disease, 
respectively  [66].  Kana  et  al.  [67]  compared  the  frequency  of  different  interactions  in  a  human 
protein-protein interaction network and found that human protein-protein interactions preferably occur 
between disordered proteins and the flexibility of the interacting protein may play an important role in 
protein interaction networks. Swasti et al. [66] have investigated the content of unstructuredness in 
three neurodegenerative diseases  datasets,  and  found significantly high prevalence of unstructured 
proteins in most of these diseases.   
Proteins that have a large number of interactions are called hubs [68]. It is obvious that hubs are 
central to the normal functions of the protein-protein interaction network in every organism. Several 
studies showed that hub proteins are implicated in diseases. The structural flexibility of IDPs allows 
them to  adopt  different  structural conformations  when bound to  different  targets and affects their Int. J. Mol. Sci. 2011, 12                         
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binding abilities [69]. For example, human α-synuclein presents partial folding with several divalent 
and trivalent mental ions [70], and it undergoes conformational change from an unstructured monomer 
in solution to organized structure when interacting with phospholipids [71]. This organized structure 
forms the basis of aggregation and fibrillation. Any factors which lead to population of this organized 
structure will increase the likelihood of α-synuclein fibril formation. Patil et al. [68] found proteins 
with a more diverse domain composition are over-represented in hubs compared with non-hubs. 
5. Drug-Discovery Pathways Based on IDPs 
5.1. IDPs Can Be Used to Design a Novel Inhibitor to Avoid Amyloid-Like Aggregation 
More  than  40  human  diseases  have  been  associated  with  the  formation  extracellular  fibrilar 
aggregates [72] that are generally known as amyloid fibrils. IDPs have a higher net charge and lower 
hydrophobicity [2], and they also have a lower number of aggregating sequences, which IDPs use 
―classical‖ strategies to avoid amyloid aggregation, providing a novel pathway to design inhibitors to 
prevent amyloid-like aggregation [73]. 
5.2. Drug Design Based on Transition from Disordered to Ordered   
The intrinsic disorder proteins could serve as potential targets for structure-based drug design which 
stress the transition from disordered to ordered confirmation through drug stimulation [74]. Two years 
ago, an unstructured domain of a regulatory protein was found to be involved in inhibiting catalytic 
activity of insulin signaling in the treatment of diabetes [75,76]. Based on the features of IDPs, they 
propose a hypothesis that disease associated proteins can be targeted for structural transition by using 
structure  based  drugs  that  mimic  the  binding  partner  of  targeted  IDPs  and  induce  moderation  in 
structure and behavior of the targeted IDP. Therefore it may be possible to alter the folding of target 
proteins to regulate its activity and ultimately its function. 
5.3. Drug Discovery Based on IDPs Interaction Networks 
Intrinsic  disorder  is  very  common  in  disease-associated  proteins,  giving  rise  to  the  disorder  in 
disorders phenomena [68,77]. Protein-protein interaction is a potential source for drug targets [64]. 
Protein interactions and understanding of the results at a deeper level may predict the interesting drug 
targets. People have been trying to develop drug molecules that block protein-protein interactions. 
Most hub proteins in interaction networks have intrinsically disordered regions. There is large local 
flexibility in partially disordered hub proteins and global flexibility in fully disordered hub proteins. 
Some hubs contain both ordered and disordered regions, and some hubs are entirely ordered [69]. For 
the highly structured hubs, the binding regions of their partner proteins are intrinsically disordered   
(ID) [78]. Intrinsic disorder is utilized in protein-protein interactions: namely, one disordered region 
binding to many partners and many disordered regions binding to one partner [78,79]. Many IDPs and 
IDRs fold upon binding with their specific partners. Protein conformational diseases may result from 
not only protein misfolding but also misidentification and mis-signaling [78].   
Alternative splicing is commonly present in several genetic diseases. Alternative splicing regions in 
corresponding proteins  are predicted to be highly disordered.  Recently several small molecules as Int. J. Mol. Sci. 2011, 12                         
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potential drugs have been shown to act by blocking protein-protein interactions based on intrinsic 
disorder  of  one  of  the  partners  [80].  Various  disease-associated  proteins  are  very  rich  in  such 
disorder-based drug discovery targets. Although there has not been any drug molecule that functions 
by inhibiting a protein-protein interactions, several promising molecules are encouraging a renewed 
interest in this approach [81]. Several interesting drug-like lead compounds apparently function by 
blocking protein-protein interactions, and these leads are being actively pursued via drug-discovery 
strategies. The p53/Mdm2 interaction has been the focus of multiple drug-discovery studies, and the 
binding region of p53 is intrinsically disordered. Bioinformatics and computational biology tools were 
employed  to  reveal  the  features  of  disordered  region  for  finding  drug-discovery  targets.  By  this 
approach, thousands of possible new drug targets involving one disordered partner were found. Lots of 
new drug targets were found for each of the major diseases [82]. The interaction between disordered 
and ordered proteins has several features that are consistent with being a good target for drug discovery. 
The interface between one structured and disordered partner is almost never flat. Such interaction is 
likely to be weaker than similar sized interaction between two structured proteins.  Protein-protein 
interactions with disordered interface regions are as new targets for drug discovery. Development of 
tissue-specific drugs by taking into account tissue-specific alternative splicing in disordered regions 
from protein-protein interaction that can be blocked by small molecules. 
Drug-discovery has been linked with the function of IDRs. New drug discovery strategies aim at 
targeting a wide variety of signaling and regulatory functions of these regions.   
5.4. Examples of Drug Discovery Based on a Few IDPs   
α-synuclein [64]: α-synuclein is a typical IDP that links various synucleinopathies. The structure of 
α-synuclein is extremely sensitive to the environment and can be easily modified. α-synuclein is an 
example of a disordered hub, and is shown to interact with at least 50 ligands and other proteins [83]. 
A  recent  proteomic  analysis  identified  587  proteins  involved  in  the  formation  of  complexes  with 
α-synuclein in the dopaminergic cells, with 141 proteins displaying significant changes in their relative 
abundance after these cells were treated with rotenone [84]. 
The orphan G protein-coupled receptor 3(GPR3) modulates amyloid beta peptide generation in 
neurons, and it represents a potential therapeutic target for the treatment of Alzheimer’s disease [85]. 
Tau protein [86]: Efforts to develop drugs that halt the relentless brain degeneration caused by 
disorders have only met with modest success so far. The approved therapies only temporarily slow 
cognitive decline, possibly because they do not target the root cause of the disease. They are aimed at 
reducing production of amyloid beta, a protein fragment thought to be the instigator of the nerve cell 
death  driving  Alzheimer’s  disease  [87].  Recently,  researches  are  taking  a  closer  look  at  another 
possible target, a protein called tau that is involved in the pathology of a number of neurodegenerative 
diseases,  including  Alzheimer’s  disease.  Drugs,  such  as  FTID,  decreases  tau  phosphorylation  and 
inhibit neurofibrillary degeneration. 
P53 protein [64]: p53 is at the center of a large network, regulating expression of genes involved in 
numerous cellular processes including cell cycle progression, apoptosis induction, DNA repair, and 
response  to  cellular  stress,  etc.  When  p53  function  is  lost,  cells  often  undergo  cancerous   
transformation [88]. A database of p53 point mutations was created. There are three structural domains 
in  p53  [89]:  N-terminal  translational  activation  domain,  central  DNA  binding  domain,  and Int. J. Mol. Sci. 2011, 12                         
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C-tramerization regulatory domain. DNA binding domain is intrinsically structured, whereas the two 
terminal domains are intrinsically disordered. P53 induces or inhibits over 150 genes. Overall, about 
70% of the interactions between p53 and its partners are mediated by IDRs in p53 [78]. A bias towards 
intrinsic disorder is even more pronounced in the site of posttranslational modifications, with 86%, 
90%, and 100% of observed acetylation, phosphorylation, and protein conjugation sites, respectively. 
p53 extensively utilizes IDRs to mediate and modulate interactions with other proteins. 
Cancer is a disease of cell biology [90]. p53 network, in response to DNA damage, provides us a 
new edificatory to study  IDPs-associated protein-protein interaction network [91], and IDPs-based 
research may provide novel pathways for cancer treatment.   
5.5. The Key Roles of Computation in Drug Discovery   
It is a fact that the use of computational methods has been involved in all aspects of drug discovery 
today [92]. With a computational tool, one can find more new drug candidates quickly at a lower cost. 
Currently, a revolutionary concept is computational unfoldomics, which is involved in IDPs discovery, 
predicting  IDPs,  computer  simulations  of  IDPs,  finding  functional  sites  in  IDPs,  fuzziness  of 
protein-protein interactions and finding order in disorder, and so on. It is obvious that computational 
unfoldomics will improve the IDPs research and promote drug discovery.   
6. Conclusions 
We  should  enlarge  our  view  of  what  constitutes  human  disease  research,  recognizing  that  the 
discoveries that have the most profound impact on disease treatments emanate from basic research on 
model organisms, rather than from studies of highly complex human diseases. The studies on IDPs 
belong to these basic researches, which could provide us novel pathways for drug discovery. However, 
it is not enough for us to design new drugs based on the current understanding of the features of IDPs. 
Therefore  it  is  crucial  to  further  reveal  novel  features  of  IDPs,  including  sequence,  structural, 
dynamics,  biophysical  and  interaction  network,  by  both  computational  and  experimental  methods. 
Drug discovery based on these novel features may reveal a bright new path.   
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